WNT8B and neoplasm: Conversely, Wnt2 and Wnt8b are downregulated at the tumor/bone interface while Wnt antagonists WIF1 and SFRP4 are overexpressed and could be responsible, at least in part, of suppression of osteoblast proliferation and enhanced bone destruction by osteoclasts [120].